A recent phosphoproteomic study in HNSCC has identified that EGFR ligands rather than the receptor are the rate-limiting factor for EGFR pathway activity, offering an explanation for this discordance (33). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.